High Poly(Adenosine Diphosphate-Ribose) Polymerase Expression and Poor Survival in Advanced-Stage Serous Ovarian Cancer
High Poly(Adenosine Diphosphate-Ribose) Polymerase Expression and Poor Survival in Advanced-Stage Serous Ovarian Cancer
复制标题
DOI：
10.1097/aog.0b013e3181c2d294
复制
发表时间：
2010-01-01
影响因子：
7.2
通讯作者：
Berchuck, Andrew
中科院分区：
文献类型：
--
作者：
Barnett, Jason C.;Bean, Sarah M.;Berchuck, Andrew
目的：估计浆液性卵巢癌中聚（腺苷二磷酸 [ADP]-核糖）聚合酶的表达范围，并确定表达是否与治疗反应和结果相关。 方法：对 186 例石蜡包埋的浆液性卵巢癌进行聚（ADP-核糖）聚合酶免疫染色。使用评估染色强度和细胞染色百分比的评分系统对核聚（ADP-核糖）聚合酶表达进行定量。进行 Kaplan-Meier 分析以评估聚（ADP-核糖）聚合酶表达与总生存期之间的关系。结果：54% 的浆液性癌中存在高聚（ADP-核糖）聚合酶表达，但与分期或分级无关。低聚（ADP-核糖）聚合酶表达的病例（70%与高聚（ADP-核糖）聚合酶表达的病例（71%）相比，初次化疗的完全临床缓解率没有差异。然而，高聚（ADP-核糖）聚合酶表达与显着较差的中位总生存期相关（36个月与43个月相比，P=.04，风险比0.71）。结论：聚（ADP-核糖）聚合酶表达卵巢癌中的聚合酶具有异质性，浆液性卵巢癌中的高表达与较差的总体生存率相关，这些数据表明，对原发性癌症中聚（ADP-核糖）聚合酶表达的评估可能允许在最有可能产生反应的患者中选择性使用聚（ADP-核糖）聚合酶抑制剂（Obstet Gynecol 2010；115：49-54）。
OBJECTIVE: To estimate the range of poly(adenosine diphosphate [ADP]-ribose) polymerase expression in serous ovarian cancers and to determine whether expression is associated with response to therapy and outcome.METHODS: Immunostaining for poly(ADP-ribose) polymerase was performed in 186 paraffin-embedded, serous ovarian cancers. Nuclear poly(ADP-ribose) polymerase expression was quantified using a scoring system that assesses both staining intensity and percentage of cells staining. Kaplan-Meier analysis was performed to evaluate the relationship between poly(ADP-ribose) polymerase expression and overall survival.RESULTS: High poly(ADP-ribose) polymerase expression was present in 54% of serous cancers but was not associated with stage or grade. There was no difference in the rate of complete clinical response to primary chemotherapy between cases with low poly(ADP-ribose) polymerase expression (70% compared with those with high poly(ADP-ribose) polymerase expression (71%). However, high poly(ADP-ribose) polymerase expression was associated with significantly worse median overall survival (36 compared with 43 months, P=.04, hazard ratio 0.71).CONCLUSION: Expression of poly(ADP-ribose) polymerase in ovarian cancers is heterogeneous, and high expression in serous ovarian cancers is associated with worse overall survival. These data suggest that evaluation of poly(ADP-ribose) polymerase expression in the primary cancer could potentially allow selective use of poly(ADP-ribose) polymerase inhibitors in patients most likely to respond. (Obstet Gynecol 2010;115:49-54)